Search

Jinsong G Ni

from Reno, NV
Age ~57
Get Report
Also known as:
Jin Song Ni, Jin-Song Ni, Ni Jin-Song
Related to:
Shoujen D Du, 65N I JinsongWan Ni, 52Tao L Wu, 57Eric Du, 36Mao S Song, 62
Connected to:
Alice Ni, 30Angela C Ni, 45Ba Ni, 72Boo R Ni, 50Carolyn L Ni, 65Chi Ni, 104Chris Ni, 36Ella O Ni, 49Fanqi Ni, 35Hu Ni, 44

Jinsong Ni Phones & Addresses

  • Reno, NV
  • 145 Cloudbreak, Irvine, CA 92618 (949) 419-7605
  • 52 Water Lily, Irvine, CA 92606 (949) 679-8408
  • 11 Del Cambrea, Irvine, CA 92606 (949) 679-8408
  • 1713 Aspen Dr, Plainsboro, NJ 08536 (609) 716-4705
  • 9 Coca, Foothill Ranch, CA 92610 (949) 305-5058 (949) 770-1686 (714) 305-5058
  • Tustin, CA
  • Salt Lake City, UT
  • Mount Kisco, NY
  • Valhalla, NY
  • 52 Water Lily, Irvine, CA 92606 (949) 305-5058

Work

Position: Food Preparation and Serving Related Occupations

Education

Degree: High school graduate or higher

Resumes

Resumes

Jinsong Ni Photo 1

Scientific Director At Allergan

View page
Position:
Scientific Director at Allergan
Location:
Orange County, California Area
Industry:
Pharmaceuticals
Work:
Allergan
Scientific Director
Jinsong Ni Photo 2

Scientific Director At Allergan

View page
Position:
Scientific Director at Allergan
Location:
Orange County, California Area
Industry:
Pharmaceuticals
Work:
Allergan since 2000
Scientific Director
Pfizer - New Jersey 1997 - 2000
Sr Scientist

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jinsong Ni
President
ICE TREE, INC
9 Coca, Foothill Ranch, CA 92610

Publications

Us Patents

9,11-Cycloendoperoxide Pro-Drugs Of Prostaglandin Analogues For Treatment Of Ocular Hypertension And Glaucoma

View page
US Patent:
20040023954, Feb 5, 2004
Filed:
Aug 5, 2002
Appl. No.:
10/212437
Inventors:
Wu Yang - Irvine CA, US
Jinsong Ni - Foothill Ranch CA, US
Haiqing Yuan - Irvine CA, US
Diane Tang-Liu - Newport Beach CA, US
International Classification:
A61K031/5575
C07D417/02
C07D413/02
C 07D 4 7/02
US Classification:
514/228200, 514/464000, 514/232200, 514/254110, 514/321000, 544/060000, 544/152000, 544/377000, 546/197000, 549/434000
Abstract:
9,11-Cycloendoperoxide derivatives of biologically active prostaglandin analogs, and particularly of the ocular hypotensive drugs Bimatoprost, Latanaprost, Unoprostone, Travoprost and prostaglandin H1-ethanolamide or of structurally closely related analogs, are pro-drugs which hydrolyze under physiological conditions to provide prostaglandin analogues that are capable of providing sustained ocular and other in vivo concentrations of the respective drugs. The compounds of the invention have the formula shown below where the variables have the meaning defined in the specification.

Compositions And Methods For Treating Pterygium Recurrence

View page
US Patent:
20210308042, Oct 7, 2021
Filed:
Apr 12, 2021
Appl. No.:
17/227877
Inventors:
- Irvine CA, US
Jinsong Ni - Irvine CA, US
International Classification:
A61K 9/00
A61F 9/00
A61K 45/06
A61K 47/26
A61K 9/06
A61K 9/08
A61K 9/10
A61K 9/107
A61K 31/404
A61K 31/407
A61K 31/496
A61P 27/00
A61P 27/02
Abstract:
Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

A Topical Composition For Treating Rosacea And A Method For Treating Rosacea With The Same

View page
US Patent:
20200121675, Apr 23, 2020
Filed:
May 25, 2018
Appl. No.:
16/616444
Inventors:
Scott WHITCUP - Irvine CA, US
Rong YANG - Mission Viejo CA, US
Jinsong NI - Irvine CA, US
International Classification:
A61K 31/496
A61K 31/44
A61K 31/4164
A61K 31/135
A61K 9/00
A61P 17/00
Abstract:
A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.

Compositions And Methods For Treating Pterygium Recurrence

View page
US Patent:
20190110984, Apr 18, 2019
Filed:
Dec 5, 2018
Appl. No.:
16/210896
Inventors:
- Irvine CA, US
Jinsong Ni - Irvine CA, US
International Classification:
A61K 9/00
A61P 27/02
A61K 31/496
A61K 31/407
A61K 31/404
A61K 9/107
A61K 9/10
A61P 27/00
A61K 9/06
A61K 47/26
A61K 45/06
A61F 9/00
A61K 9/08
Abstract:
Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Antibody-Drug Synergism Technology For Treating Diseases

View page
US Patent:
20190030179, Jan 31, 2019
Filed:
Feb 2, 2017
Appl. No.:
16/072415
Inventors:
Jinsong NI - Irvine CA, US
Rong YANG - Mission Viejo CA, US
International Classification:
A61K 47/68
C07K 16/22
A61K 39/395
A61K 31/496
Abstract:
A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.

Compositions And Methods For Treating Hyperemia

View page
US Patent:
20180271780, Sep 27, 2018
Filed:
May 29, 2018
Appl. No.:
15/991382
Inventors:
- Irvine CA, US
Jinsong Ni - Irvine CA, US
International Classification:
A61K 9/00
A61K 31/407
A61K 31/496
A61P 27/00
A61K 31/404
A61F 9/00
A61K 45/06
A61K 47/26
A61K 9/107
A61K 9/10
A61K 9/08
A61K 9/06
Abstract:
Compositions and methods for treating hyperemia and symptoms in pinguecula and pseudopteryigium are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Compositions And Methods For Treating Pterygium

View page
US Patent:
20180271781, Sep 27, 2018
Filed:
May 29, 2018
Appl. No.:
15/991698
Inventors:
- Irvine CA, US
Jinsong Ni - Irvine CA, US
International Classification:
A61K 9/00
A61K 9/107
A61K 47/26
A61K 45/06
A61K 31/496
A61K 31/407
A61K 31/404
A61P 27/00
A61K 9/10
A61K 9/08
A61K 9/06
A61F 9/00
Abstract:
Compositions and methods for treating hyperemia and symptoms in pterygium patients are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Compositions And Methods For Treating Pterygium

View page
US Patent:
20170209368, Jul 27, 2017
Filed:
Mar 30, 2017
Appl. No.:
15/474620
Inventors:
- Irvine CA, US
Jinsong Ni - Irvine CA, US
International Classification:
A61K 9/00
A61K 9/08
A61K 31/407
A61K 9/107
A61K 31/496
A61K 31/404
Abstract:
Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.
Control profile
Jinsong G Ni from Reno, NV, age ~57 Get Report